News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
Partner Content Partner Content Positive PIII results for VYXEOS revealed at ASCO Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
